Arete Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,480	Closed	-$392K	–	401
2025 Q4	$392K	Buy	7,480 +110	+1%	+$6.59K	0.02%	510
2025 Q3	$478K	Buy	7,370 +1,642	+29%	+$94.3K	0.03%	459
2025 Q2	$279K	Buy	+5,728	New	+$222K	0.02%	585
2024 Q4	–	Sell	-10,376	Closed	-$486K	–	757
2024 Q3	$486K	Sell	10,376 -388	-4%	-$19.7K	0.04%	383
2024 Q2	$578K	Sell	10,764 -133	-1%	-$7.69K	0.05%	353
2024 Q1	$743K	Sell	10,897 -115	-1%	-$8.23K	0.07%	251
2023 Q4	$689K	Sell	11,012 -589	-5%	-$32.6K	0.05%	325
2023 Q3	$527K	Buy	11,601 +870	+8%	+$44.9K	0.09%	227
2023 Q2	$602K	Sell	10,731 -283	-3%	-$16.1K	0.05%	325
2023 Q1	$498K	Buy	11,014 +5,353	+95%	+$260K	0.04%	343
2022 Q4	$230M	Sell	5,661 -2,160	-28%	-$115K	0.02%	526
2022 Q3	$511K	Buy	7,821 +1,153	+17%	+$83.6K	0.05%	294
2022 Q2	$405K	Buy	+6,668	New	+$392K	0.04%	282
2021 Q4	–	Sell	-2,506	Closed	-$277K	–	506
2021 Q3	$277K	Buy	2,506 +54	+2%	+$6.78K	0.03%	340
2021 Q2	$303K	Buy	+2,452	New	+$298K	0.04%	263
2021 Q1	–	Sell	-1,598	Closed	-$250K	–	424
2020 Q4	$250K	Buy	+1,598	New	+$189K	0.04%	341